<DOC>
	<DOCNO>NCT00132938</DOCNO>
	<brief_summary>Primary Objective : - The primary objective study demonstrate superiority telithromycin azithromycin cefuroxime axetil reduction Streptococcus pneumoniae ( Sp ) strain resistant beta-lactams macrolides Test Cure ( TOC ) visit sputum patient Sp detect start study ( Visit 1 ) . Secondary Objectives : The secondary objective study : - To demonstrate superiority telithromycin azithromycin cefuroxime axetil achieve clinical cure Sp eradication success Test Cure visit patient Sp detect sputum specimen start study ( Visit 1 ) ; - To compare clinical cure rate achieve treatment group penicillin erythromycin resistant Sp ( PERSp ) population cure rate sensitive Sp ( SSp ) population End Therapy ( EOT ) Test Cure visit ; - To compare effect telithromycin , azithromycin cefuroxime axetil End Therapy visit presence Streptococcus pneumoniae strain resistant beta-lactams macrolides sputum patient Sp detect start study ( Visit 1 ) ; - To compare clinical efficacy End Therapy visit safety Test Cure visit telithromycin , azithromycin cefuroxime axetil `` global '' randomize population .</brief_summary>
	<brief_title>PERSPECTIVE : Telithromycin - Acute Exacerbation Chronic Bronchitis</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Telithromycin</mesh_term>
	<criteria>Patients meet follow criterion consider enrollment study : Outpatients , male female , age 35 year old Patients document history chronic bronchitis , characterize cough excessive sputum production day least three month 2 consecutive year Patients clinical diagnosis acute exacerbation chronic bronchitis ( AECB ) , presume due bacterial infection base increase sputum purulence either increase dyspnea sputum volume Patients produce spontaneous sputum Patients three less AECB previous 12 month Patients present follow include study : Patients know diagnosis bronchiectasis ; cystic fibrosis ; lung cancer lung metastasis ; active pulmonary tuberculosis ; suspect pneumonia . Patients present acute respiratory failure patient require aggressive airway management Hospitalized patient patient institutional care facility Patients treat antibiotic within 14 day prior enrollment Patients receive medication , include systemic antimicrobial agent ; disease condition infection could interfere evaluation drug efficacy safety . Patients concomitant condition ( include clinically relevant cardiovascular , hepatic , neurologic , endocrine , major systemic disease ) make either implementation protocol interpretation study result difficult Patients progressively fatal disease , life expectancy ≤ three month Patients receive investigational drug within 1 month prior study entry , treatment plan study period Patients recent ( within previous three month ) history alcohol drug abuse Immunocompromised patient include , limited : patient know HIV infection ( CD4 + &lt; 200/mm3 ) ; know neutropenia ( &lt; 1500 neutrophils/mm3 ) ; chronic corticosteroid therapy ( ≥ 10mg/day prednisolone equivalent least three month ) ; immunodepressant treatment within previous six month ; splenectomized patient patient know hyposplenia asplenia . Patients mental condition render unable understand nature , scope , possible consequence study Patients unlikely comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikely complete study Patients receive antipneumococcal immunization previous six month study entry Patients suspect known hypersensitivity , suspect serious adverse reaction study medication , ßlactams macrolide class antibiotic Patients diagnose myasthenia gravis Women breastfeed pregnant Women childbearing potential agree use approve contraceptive method study Patients galactose intolerance , lactase deficiency glucosegalactose malabsorption Patients know history long QTc syndrome ( e.g. , personal family history syncope arrhythmia ) Patients treat within 2 week prior study entry , require treatment study medication , CYP3A4 inducer rifampicin , phenytoin , carbamazepine , phenobarbital , St John 's wort Patients require treatment study period drug permit clinical study protocol Patients know impaired hepatic function Patients know impaired renal function Patients already enrol study</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>